Cyclacel Begins Phase I Pharmacologic Study Of Oral Sapacitabine In Patients With Advanced Leukemias SHORT HILLS, NJ, JUNE 15, 2006 – Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC) announced today that the company has initiated a Phase I clinical trial of sapacitabine (CYC682), an orally available
Cyclacel Pharmaceuticals To Present At 5th Annual Needham & Company, LLC Biotechnology & Medical Technology Conference 2006 SHORT HILLS, NJ, JUNE 12, 2006 – Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC) announced today that Spiro Rombotis, President and Chief Executive Officer, will present an
Cyclacel Pharmaceuticals To Present At Bioequity Europe 2006 SHORT HILLS, NJ, MAY 18, 2006 – Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC) announced today that Paul McBarron, Executive Vice President, Finance and Chief Operating Officer, will present an overview of the Company and its pipeline at
Cyclacel Pharmaceuticals To Present At Rodman And Renshaw 3rd Annual Global Healthcare Conference SHORT HILLS, NJ, MAY 4, 2006 – Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC) announced today that Spiro Rombotis, President and Chief Executive Officer, will present an overview of the Company and its
Cyclacel Pharmaceuticals Announces $45 Million Private Placement SHORT HILLS, NJ, April 27, 2006 – Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC) announced today that the Company has entered into a definitive agreement to raise approximately $45.3 million in a private placement of approximately 6.43
Cyclacel Pharmaceuticals, Inc. Announces Quarterly Dividend For 6% Convertible Exchangeable Preferred Stock SHORT HILLS, NJ, APRIL 19, 2006 – Cyclacel Pharmaceuticals, Inc. ("Cyclacel", the "Company") (Nasdaq: CYCC) (Nasdaq: CYCCP) announced today that the Company's Board of Directors has declared
Cyclacel Pharmaceuticals To Present At BIO 2006 Annual International Convention SHORT HILLS, NJ, APRIL 6, 2006 – Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC) announced today that Spiro Rombotis, President and Chief Executive Officer, will present an overview of the Company and its pipeline at the
Cyclacel Pharmaceuticals Established With Completion Of Cyclacel Group Plc And Xcyte Therapies Transactions SHORT HILLS, NJ March 28, 2006 – Cyclacel Group plc announced today that it has completed the previously announced transactions with Xcyte Therapies, Inc.
Cyclacel Pharmaceuticals Begins Trading On NASDAQ With CYCC Ticker Symbol SHORT HILLS, NJ, MARCH 28, 2006 – Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC) announced today that it will begin trading this morning on the Nasdaq National Market system. Cyclacel common shares will trade under the ticker
Delicious
Digg
Facebook
LinkedIn
Twitter